Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Dec 24, 2025
Reporting period
Not applicable
Filed with the SEC
Dec 30, 2025
OfficerTax withholding
Context
Classification
tax withholding
Code F — shares delivered to pay exercise price or tax liability
Planned / mechanical clue
Tax mechanics (code F)
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001193125-25-335575
Filed / recorded
Dec 30, 2025, 3:58 AM UTC
Added to OQRO
Oct 6, 2026, 7:14 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
CORCEPT THERAPEUTICS INC
Issuer CIK
1088856
Ticker
CORT
Reporting person
Gary Charles Robb
Relationship
Officer
Officer title
Chief Business Officer
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Dec 24, 2025
Transaction code
F
Shares / units
80,284
Price per share
$83.59
Acquired / disposed
Disposed (D)
Shares owned after
78,626
Ownership form
Direct
Amendment
No
Footnotes from the filing
These shares were withheld so the Reporting Person could satisfy the exercise price and tax liability from a net (cashless) exercise of options.
Includes 292 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 997 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, and 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.